VCYT

VERACYTE, INC.

Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

SectorHealthcare
IndustryMedical - Diagnostics & Research
Market Cap$3.9B
Last DividendNone
Employees755
CEOMarc Stapley

Valuation

Current Price$47.93
Fair Value?$000.00
Valuation?No valuation
Current PE ?33.28
Hist. PE ?N/Aⓘ
EPS (TTM) ?1.44
Forward EPS Growth ?5.65%
Historical Growth ?52.80%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro

Price?

EPS?

Revenue?

Equity?

Pro

Available on the Pro plan

Free Cash Flow?

Pro

Available on the Pro plan

Long Term Debt?

Pro

Available on the Pro plan

Net Profit?

Pro

Available on the Pro plan

Shares Outstanding?

Pro

Available on the Pro plan

Last updated: 10/23/2026, 11:17:42 PM